Clinical Trial Update: Standard of Care vs. Bortezomib in Graft-Versus Host Disease After Hematopoietic Stem Cell Transplant [Phase 2]

View source ↗

Summary

Phase 2 trial comparing standard of care versus bortezomib for graft-versus-host disease after hematopoietic stem cell transplantation; the study is completed w…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Graft-versus-host Disease

Drugs mentioned

• Bortezomib (bortezomib)

Snippet

Sponsor: Dana-Farber Cancer Institute | Conditions: Graft Versus Host Disease | Phase 2 | Status: COMPLETED | Results posted: 2017-07-18